Importance of extracardiac alpha1-adrenoceptor stimulation in assisting dofetilide to induce torsade de pointes in rabbit hearts.
In anaesthetized rabbits, alpha(1)-adrenoceptor stimulation increases the propensity of repolarization-prolonging drugs to induce torsade de pointes ventricular tachycardia. However, it is not known whether the stimulation of intracardiac alpha(1)-adrenoceptors, or the increased ventricular stretch caused by extracardiac alpha(1)-adrenoceptor-mediated peripheral vasoconstriction and increased resistance, are the sensitizing factors. Accordingly, this study investigated whether a sustained load-induced left ventricular stretch or stimulation of the intracardiac alpha(1)-adrenoceptors with 100 nM methoxamine, or the co-application of these two, can assist dofetilide (100 nM) to elicit torsade de pointes in isolated Langendorff-perfused, rabbit hearts. In the stretched hearts, a constant high level of stretch was produced by a water-filled left ventricular balloon inflated to a volume of 1.4 ml, whereby the systolic and end-diastolic pressures virtually did not exceed the physiological range (<or=157+/-11 mm Hg and <or=9+/-2 mm Hg, respectively; mean+/-S.E.M.). Perfusion with dofetilide prolonged the QT interval significantly and indifferently in all hearts. Neither this stretch nor methoxamine nor the in combination affected the QT interval, the heart rate or the coronary flow. Interestingly, neither the stretch ('dofetilide+stretch' group, n=8 hearts), nor methoxamine ('dofetilide+methoxamine' group, n=8 hearts), nor the in combination ('dofetilide+stretch+methoxamine' group, n=8 hearts) elevated the incidence of torsade de pointes as compared with the 'dofetilide alone' group (n=9 hearts) (0%, 25%, 0%, versus 44%, respectively). In conclusion, neither a sustained load-induced stretch nor alpha(1)-adrenoceptor stimulation nor the in combination assisted dofetilide to induce torsade de pointes in isolated rabbit hearts, suggesting the importance of extracardiac alpha(1)-adrenoceptor stimulation in this phenomenon.
Farkas
Attila S
AS
2nd Department of Internal Medicine and Cardiology Centre, Faculty of Medicine, University of Szeged, Korányi fasor 6., Szeged, H-6701, Hungary.
Acsai
Károly
K
Tóth
András
A
Dézsi
László
L
Orosz
Szabolcs
S
Forster
Tamás
T
Csanády
Miklós
M
Papp
Julius Gy
JG
Varró
András
A
Farkas
András
A
D058646:Adrenergic alpha-1 Receptor Agonists; D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D004562:Electrocardiography; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006352:Heart Ventricles / Q000187:drug effects* / Q000503:physiopathology; D066298:In Vitro Techniques; D008729:Methoxamine / Q000494:pharmacology; D010627:Phenethylamines / Q000494:pharmacology*; D011817:Rabbits; D018340:Receptors, Adrenergic, alpha-1 / Q000502:physiology; D012039:Regional Blood Flow / Q000187:drug effects; D013449:Sulfonamides / Q000494:pharmacology*; D016171:Torsades de Pointes / Q000139:chemically induced / Q000503:physiopathology*
D058646:Adrenergic alpha-1 Receptor Agonists; D000316:Adrenergic alpha-Agonists; D000889:Anti-Arrhythmia Agents; D010627:Phenethylamines; D018340:Receptors, Adrenergic, alpha-1; D013449:Sulfonamides; D008729:Methoxamine; C063533:dofetilide